Literature DB >> 6692404

Preparation and interaction of a low-density lipoprotein:daunomycin complex with P388 leukemic cells.

M J Iwanik, K V Shaw, B J Ledwith, S Yanovich, J M Shaw.   

Abstract

A low-density lipoprotein (LDL):daunomycin complex was prepared which contains, on the average, 8 nmol of daunomycin/mg of apolipoprotein. LDL was not perturbed to any significant degree by association with daunomycin, and the complex remained stable at 4 degrees. Fluorescence quenching with DNA and potassium iodide, antibody precipitation, and density flotation studies suggested at least two domains for localization of the daunomycin, the surface region and the hydrophobic core of the LDL particle. Interaction of the LDL:daunomycin complex with P388 leukemic cells which were sensitive or resistant to daunomycin occurred rapidly in both sublines, with quantitatively larger amounts of the drug being cell associated than when free drug was used alone. The cells appeared morphologically intact, with no nuclear damage after short-term incubation with LDL:daunomycin. Subfractionation of cell membranes and organelles from the sensitive and resistant cell lines incubated with LDL:daunomycin showed accumulation of drug in the plasma membrane and microsomal-lysosomal-mitochondrial membranes and an insoluble nuclear chromatin material. Both 125l-labeled apoprotein and daunomycin from a 125l-LDL:daunomycin complex showed enrichment in similar membrane:organelle fractions of the P388 cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692404

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Antitumoral activity of low density lipoprotein-aclacinomycin complex in mice bearing H(22) tumor.

Authors:  Wen-Xiang Bi; Song-De Xu; Pei-Hai Zhang; Feng Kong
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting.

Authors:  S A Ford; P J Russell; M Jelbart; D Raghavan
Journal:  Urol Res       Date:  1989

3.  Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.

Authors:  J M Shaw; W S Futch; L B Schook
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

4.  The distribution of porphyrins with different tumour localising ability among human plasma proteins.

Authors:  M Kongshaug; J Moan; S B Brown
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

5.  Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.

Authors:  S Vitols; K Söderberg-Reid; M Masquelier; B Sjöström; C Peterson
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

6.  Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles.

Authors:  Meng Liang; Chunhong Gao; Yuli Wang; Wei Gong; Shiyao Fu; Lin Cui; Zhenhan Zhou; Xiaoyang Chu; Yue Zhang; Qianqian Liu; Xiong Zhao; Baoquan Zhao; Meiyan Yang; Zhiping Li; Chunrong Yang; Xiangyang Xie; Yang Yang; Chunsheng Gao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 7.  A chemical perspective on the anthracycline antitumor antibiotics.

Authors:  B R Abdella; J Fisher
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

8.  Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.

Authors:  M Samadi-Baboli; G Favre; P Canal; G Soula
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

9.  Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer.

Authors:  L A Pires; R Hegg; F R Freitas; E R Tavares; C P Almeida; E C Baracat; R C Maranhão
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.